Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Managed Health Care2.01%-0.36 ppLife Sciences Tools & Services1.64%-0.36 ppPharmaceuticals4.92%-0.29 ppHealth Care Services0.67%-0.20 ppBiotechnology2.51%-0.17 ppHealth Care Equipment3.01%+0.07 ppHealth Care Distributors0.44%+0.03 ppHealth Care Facilities0.24%-0.00 ppHealth Care Supplies0.16%+0.00 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.51%
Industry change · 12M
-0.17 pp
Biotechnology · contribution
-0.174 pp
Company participation
63%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Jan 2024 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Moderna → MRNA | United States | $38.5bn | 0.115% | +0.016 pp | -0.117 pp | -42.6% | Yes |
| Gilead Sciences → GILD | United States | $97.5bn | 0.290% | -0.043 pp | -0.070 pp | -3.2% | No |
| Vertex Pharmaceuticals → VRTX | United States | $111.7bn | 0.332% | +0.014 pp | +0.048 pp | +34.1% | Yes |
| Amgen → AMGN | United States | $168.2bn | 0.500% | +0.035 pp | +0.039 pp | +28.8% | Yes |
| Biogen → BIIB | United States | $35.7bn | 0.106% | -0.011 pp | -0.037 pp | -15.2% | No |
| AbbVie → ABBV | United States | $290.3bn | 0.863% | +0.016 pp | -0.031 pp | +15.8% | Yes |
| Incyte → INCY | United States | $13.2bn | 0.039% | -0.002 pp | -0.026 pp | -31.0% | No |
| Regeneron Pharmaceuticals → REGN | United States | $88.6bn | 0.263% | +0.014 pp | +0.019 pp | +24.3% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.